Orexigen(R) Therapeutics Announces Third Quarter 2009 Financi...(Property and equipment net ...),Health

Date:11/4/2009

Property and equipment, net 1,441 2,059 Restricted cash 1,290 1,375 Other assets 689 1,123 --- ----- Total assets $113,195 $91,908 ======== ======= Liabilities and stockholders' equity Current liabilities: Accounts payable and accrued expenses $10,562 $18,810 Deferred revenue, current portion 88 88 Long-term debt, current portion 7,184 7,591 ----- ----- Total current liabilities 17,834 26,489 Deferred revenue, less current portion 993 1,058 Long-term debt, less current portion 3,741 8,800 Other long-term liabilities 1,775 1,767 Commitments and contingencies Stockholders' equity: Preferred stock, $.001 par value, 10,000,000 shares authorized at September 30, 2009 and December 31, 2008; no shares issued and outstanding at September 30, 2009 and December 31, 2008 - - Common stock, $.001 par value, 100,000,000 shares authorized at September 30, 2009 and December 31, 2008; 47,039,720 and 34,433,322 shares issued and outstanding at September 30, 2009 and December 31, 2008, respectively 47 34 Additional paid-in capital 340,495 253,782 Accumulated other comprehensive income 27 153 Deficit accumulated duri
'/>"/>

SOURCE Orexigen Therapeutics, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related medicine technology :

1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
2. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
3. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
4. Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
5. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
6. Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007